2-amino-4-phenyl-5H-indeno[1, 2-d]pyrimidin-5-one | 713514-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-amino-4-phenyl-5H-indeno[1, 2-d]pyrimidin-5-one
• 英文别名: 2-amino-4-phenyl-indeno[1,2-d]pyrimidin-5-one；2-Amino-4-phenylindeno[1,2-d]pyrimidin-5-one
• CAS: 713514-58-0
• 化学式: C₁₇H₁₁N₃O
• 分子量: 273.294
• InChiKey: UVUYDEPVVFJIAY-UHFFFAOYSA-N

物化性质

• 沸点：
  595.0±58.0 °C(Predicted)
• 密度：
  1.374±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-4-phenyl-5H-indeno[1, 2-d]pyrimidin-5-one 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以100%的产率得到2-Amino-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-ol
  参考文献：
  名称：

  The discovery and synthesis of novel adenosine receptor (A2A) antagonists

  摘要：

  In high throughput screening of our file compounds, a novel structure 1 was identified as a potent A(2A) receptor antagonist with no selectivity over the A(1) adenosine receptor. The structure-activity relationship investigation using 1 as a template lead to identification of a novel class of compounds as potent and selective antagonists of A(2A) adenosine receptor. Compound 26 was identified to be the most potent A(2A) receptor antagonist (K-i = 0.8 nM) with 100-fold selectivity over the A(1) adenosine receptor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.019
• 作为产物：
  描述：

  盐酸胍 、 2-(苯基亚甲基)茚-1,3-二酮 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 2-amino-4-phenyl-5H-indeno[1, 2-d]pyrimidin-5-one
  参考文献：
  名称：

  Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists

  摘要：

  A novel series of arylindenopyrimidines were identified as A(2A) and A(1) receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson's disease when dosed orally. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.042

文献信息

• [EN] ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST<br/>[FR] ARYLINDENOPYRIDINES ET ARYLINDENOPYRIMIDINES ET LEUR UTILISATION EN TANT QU'ANTAGONISTE DES RECEPTEURS D'ADENOSINE A2A
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2005042500A1

  公开（公告）日：2005-05-12

  This invention provides novel arylindenopyridines and arylindenopyrimidines of formula (I), (II) wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.

  该发明提供了新颖的芳基吲哚吡啶和芳基吲哚嘧啶，化学式为(I)、(II)，其中R1、R2、R3、R4和X如上定义，并包括同样的药物组合物，用于治疗通过拮抗腺苷A2a受体改善的疾病。该发明还提供了使用这些化合物和药物组合物的治疗和预防方法。
• [EN] ARYLINDENOPYRIMIDINES FOR TREATING NEURODEGENERATIVE AND MOVEMENT DISORDERS WHILE MINIMIZING CARDIAC TOXICITY<br/>[FR] ARYLINDENOPYRIMIDINES POUR TRAITER LES TROUBLES NEURODÉGÉNÉRATIFS ET LES TROUBLES DU MOUVEMENT TOUT EN LIMITANT LA TOXICITÉ CARDIAQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159302A1

  公开（公告）日：2011-12-22

  This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  这项发明提供了化合物的新型芳基吲哚吡咯并吡嘧啶（Formula (I)）以及包含这些化合物的药物组合物，用于治疗通过拮抗腺苷A1和/或A2a受体而改善的疾病。该发明还提供了使用这种药物组合物的治疗和预防方法。
• ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
  申请人：JACKSON Paul

  公开号：US20110312956A1

  公开（公告）日：2011-12-22

  This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  这项发明提供了化合物的新颖芳基吲哚吡咯啉酮类化合物（式（I）），以及包含这些化合物的药物组合物，用于治疗通过拮抗腺苷A1和/或A2a受体而改善的疾病。该发明还提供了使用这种药物组合物进行治疗和预防的方法。
• Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
  申请人：——

  公开号：US20040127510A1

  公开（公告）日：2004-07-01

  This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: 1 wherein R 1 , R 2 , R 3 , R 4 , and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.

  这项发明提供了新颖的芳基吲哚吡啶和芳基吲哚嘧啶，化学式如下：1其中R1、R2、R3、R4和X如上所定义，以及包含它们的药物组合物，用于治疗通过拮抗腺苷A2a受体改善的疾病。该发明还提供了使用这些化合物和药物组合物的治疗和预防方法。
• Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives
  作者：Santosh S. Undare、Navanath J. Valekar、Ajinkya A. Patravale、Dattatraya K. Jamale、Sunil S. Vibhute、Laxman S. Walekar、Govind B. Kolekar、M.B. Deshmukh、Prashant V. Anbhule

  DOI：10.1016/j.bmcl.2015.12.088

  日期：2016.2

  Objective of the present work was to evaluate the anti-inflammatory, ulcerogenicity and cyclooxygenase activity of indenopyrimidine derivatives. Anti-inflammatory activity of the tested compounds is investigated by carrageenan-induced rat paw edema assay. Compounds A1, A6, A7 and A12 exhibit the comparable anti-inflammatory activity (79.33-81.33%) to the standard drug diclofenac sodium (85.33%), while A6, A7, A9, A12 and A14 show better ulcer index than the reference standard diclofenac sodium. To rationalize the anti-inflammatory activity, docking experiments are performed to study the ability of these compounds to bind into the active site of COX-2 enzyme. (C) 2015 Elsevier Ltd. All rights reserved.